Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves' hyperthyroidism: a randomized trial and a risk-scoring model.
Graves’ disease
Methimazole
Predictor
Recurrence
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
02 Jan 2024
02 Jan 2024
Historique:
received:
23
05
2023
accepted:
10
12
2023
medline:
2
1
2024
pubmed:
2
1
2024
entrez:
2
1
2024
Statut:
aheadofprint
Résumé
In Graves' disease, administration of low-dose methimazole for more than 60 months induces higher remission rates compared with the conventional duration of 12-18 months. However, the risk of recurrence and its predictors beyond 48 months of drug withdrawal are not known. The aims of this study were to determine the risk of recurrence during 84 months after withdrawal of short- or long-term methimazole therapy and a risk stratification for recurrence of hyperthyroidism. A total of 258 patients were treated with methimazole for a median of 18 months and randomized to discontinuation of the drug(conventional short-term group; n = 128) or continuation of the treatment up to 60-120 months(long-term group; n = 130). Patients were followed for 84 months after methimazole withdrawal. Cox proportional hazards modeling was performed to identify factors associated with relapse and develop a risk-scoring model at the time of discontinuing the treatment. Hyperthyroidism recurred in 67 of 120(56%) of conventionally-treated patients versus 20 of 118(17%) of those who received long-term methimazole treatment, p < 0.001. Age, sex, goiter grade, triiodothyronine, thyrotropin, and thyrotropin receptor antibodies were significant predictors of recurrence in both "conventional" and "long-term" groups but free thyroxine just in the "long-term" group. The risk-scoring model had a good discrimination power (optimism corrected c-index = 0.78,95%CI = 0.73-0.82) with a range of 0-14 and sensitivity of 86% and specificity of 62% at the risk-score of eight. A relapse-free state was achieved in 83% of patients with Graves' hyperthyroidism 84 months after cessation of long-term methimazole treatment which could be predicted by some significant predictors in a simple risk-scoring system.
Identifiants
pubmed: 38165576
doi: 10.1007/s12020-023-03656-5
pii: 10.1007/s12020-023-03656-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
J.P. Brito, S. Payne, N. Singh Ospina, R. Rodriguez-Gutierrez, S. Maraka, L.R. Sangaralingham, N.M. Iñiguez-Ariza, V.M. Montori, M.N. Stan, Patterns of use, efficacy, and safety of treatment options for patients with Graves’ disease: a nationwide population-based study. Thyroid 30(3), 357–364 (2020)
doi: 10.1089/thy.2019.0132
pubmed: 31973681
C.M. van Kinschot, V.R. Soekhai, E.W. de Bekker-Grob, W.E. Visser, R.P. Peeters, T.M. van Ginhoven, C. van Noord, Preferences of patients and clinicians for treatment of Graves’ disease: a discrete choice experiment. Eur. J. Endocrinol. 184(6), 803–812 (2021)
doi: 10.1530/EJE-20-1490
pubmed: 33780350
F. Azizi, R. Malboosbaf, Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid 27(10), 1223–1231 (2017)
doi: 10.1089/thy.2016.0652
pubmed: 28699478
F. Azizi, V. Yousefi, A. Bahrainian, F. Sheikholeslami, M. Tohidi, Y. Mehrabi, Long-term continuous methimazole or radioiodine treatment for hyperthyroidism. Arch. Iran. Med. 15(8), 0–0 (2012)
O.M. El Kawkgi, D.S. Ross, M.N. Stan, Comparison of long‐term antithyroid drugs versus radioactive iodine or surgery for Graves’ disease: a review of the literature. Clin. Endocrinol. 95(1), 3–12 (2021)
doi: 10.1111/cen.14374
D. Villagelin, J.H. Romaldini, R.B. Santos, A.B. Milkos, L.S. Ward, Outcomes in relapsed Graves’ disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid 25(12), 1282–1290 (2015)
doi: 10.1089/thy.2015.0195
pubmed: 26414885
F. Azizi, A. Amouzegar, M. Tohidi, M. Hedayati, D. Khalili, L. Cheraghi, Y. Mehrabi, M. Takyar, Increased remission rates after long-term methimazole therapy in patients with Graves’ disease: results of a randomized clinical trial. Thyroid 29(9), 1192–1200 (2019)
doi: 10.1089/thy.2019.0180
pubmed: 31310160
G.J. Kahaly, L. Bartalena, L. Hegedüs, L. Leenhardt, K. Poppe, S.H. Pearce, 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur. Thyroid J. 7(4), 167–186 (2018)
doi: 10.1159/000490384
pubmed: 30283735
pmcid: 6140607
D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Laurberg, A.L. Maia, S.A. Rivkees, M. Samuels, J.A. Sosa, M.N. Stan, 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10), 1343–1421 (2016)
doi: 10.1089/thy.2016.0229
pubmed: 27521067
F. Azizi, H. Abdi, A. Amouzegar, Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial. BMC Endocr. Disord. 21(1), 1–7 (2021)
doi: 10.1186/s12902-020-00670-w
T. Konishi, Y. Okamoto, M. Ueda, Y. Fukuda, I. Harusato, Y. Tsukamoto, N. Hamada, Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves’ disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr. J. 58(2), 95–100 (2011)
doi: 10.1507/endocrj.K10E-262
pubmed: 21206137
D. Maugendre, A. Gatel, L. Campion, C. Massart, I. Guilhem, Y. Lorcy, J. Lescouarch, J. Herry, H. Allannic, Antithyroid drugs and Graves’ disease—prospective randomized assessment of long‐term treatment. Clin. Endocrinol. 50(1), 127–132 (1999)
doi: 10.1046/j.1365-2265.1999.00629.x
E. Mazza, M. Carlini, D. Flecchia, A. Blatto, O. Zuccarini, S. Gamba, S. Beninati, M. Messina, Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J. Endocrinol Investig. 31(10), 866–872 (2008)
doi: 10.1007/BF03346433
K. Shizume, M. Irie, S. Nagataki, F. Matsuzaki, Y. Shishiba, H. Suematsu, T. Tsushima, Long-term result of antithyroid drug therapy for Grave’s disease follow up after more than 5 years. Endocrinol Japonica 17(5), 327–332 (1970)
doi: 10.1507/endocrj1954.17.327
K. Okamura, S. Bandai, M. Fujikawa, K. Sato, H. Ikenoue, T. Kitazono, Long-term antithyroid drug treatment: Trends in serum TSH and TSH receptor antibody changes in patients with Graves' disease. Int. J. Endocrinol. Metab. 18(Suppl), e101139:1–8 (2020)
doi: 10.5812/ijem.101139
C. Perez, N.S. Scrimshaw, J. Munoz, Technique of endemic goitre surveys. Monogr. Ser. World Health Organ 44, 369–383 (1960)
pubmed: 14431793
D. Hermsen, M. Broecker-Preuss, M. Casati, J.C. Mas, A. Eckstein, D. Gassner, J. van Helden, K. Inomata, J. Jarausch, J. Kratzsch, Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies. Clin. Chim. Acta 401(1-2), 84–89 (2009)
doi: 10.1016/j.cca.2008.11.025
pubmed: 19091299
A. Amouzegar, H. Delshad, L. Mehran, M. Tohidi, F. Khafaji, F. Azizi, Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: a population based study. J. Endocrinol Investig. 36(11), 950–954 (2013)
E. Piantanida, A. Lai, L. Sassi, D. Gallo, E. Spreafico, M. Tanda, L. Bartalena, Outcome prediction of treatment of Graves’ hyperthyroidism with antithyroid drugs. Horm. Metab. Res. 47(10), 767–772 (2015)
doi: 10.1055/s-0035-1555759
pubmed: 26197855
D.G. Kleinbaum, Epidemiologic methods: the “art” in the state of the art. J. Clin. Epidemiol. 55(12), 1196–1200 (2002)
doi: 10.1016/S0895-4356(02)00529-2
pubmed: 12547449
Steyerberg E.W.: Overfitting and optimism in prediction models. In: Clinical prediction models. Springer; 2019: 95-112.
K.P. Burnham, D.R. Anderson, Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res. 33(2), 261–304 (2004)
doi: 10.1177/0049124104268644
U. Feldt-Rasmussen, H. Schleusener, P. Carayon, Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves’ disease. J. Clin. Endocrinol. Metab. 78(1), 98–102 (1994)
pubmed: 8288723
O. Törring, L. Tallstedt, G. Wallin, G. Lundell, J.-G. Ljunggren, A. Taube, M. Sääf, B. Hamberger, Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine–a prospective, randomized study. Thyroid Study Group. J. Clin. Endocrinol. Metab. 81(8), 2986–2993 (1996)
pubmed: 8768863
P.-W. Wang, Prediction of relapse after antithyroid drugs withdrawal: A narrative review. Int. J. Endocrinol. Metab. 18(Suppl), e102346:1–8 (2020)
doi: 10.5812/ijem.102346
A.K. Eckstein, H. Lax, C. Lösch, D. Glowacka, M. Plicht, K. Mann, J. Esser, N.G. Morgenthaler, Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin. Endocrinol. 67(4), 607–612 (2007)
doi: 10.1111/j.1365-2265.2007.02933.x
N.N.Z. Tun, G. Beckett, N.N. Zammitt, M.W. Strachan, J.R. Seckl, F.W. Gibb, Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves’ disease relapse. Thyroid 26(8), 1004–1009 (2016)
doi: 10.1089/thy.2016.0017
pubmed: 27266892
B. Quadbeck, R. Hoermann, U. Roggenbuck, S. Hahn, K. Mann, O.E. Janssen, Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves’ disease. Thyroid 15(9), 1047–1054 (2005)
doi: 10.1089/thy.2005.15.1047
pubmed: 16187913
C. Carella, G. Mazziotti, F. Sorvillo, M. Piscopo, M. Cioffi, P. Pilla, R. Nersita, S. Iorio, G. Amato, L. Braverman, Serum thyrotropin receptor antibodies concentrations in patients with Graves’ disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 16(3), 295–302 (2006)
doi: 10.1089/thy.2006.16.295
pubmed: 16571093
F. Azizi, Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience. Thyroid 30(10), 1451–1457 (2020)
doi: 10.1089/thy.2019.0814
pubmed: 32253999
F. Azizi, H. Abdi, L. Mehran, A. Amouzegar, Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review. J. Endocrinol. Investig. 45(6), 1139–1150 (2022)
doi: 10.1007/s40618-021-01730-1
D.S. Cooper, Long-term antithyroid drug therapy. Curr. Opin. Endocrinol., Diabetes Obes. 28(5), 510–516 (2021)
doi: 10.1097/MED.0000000000000656
pubmed: 34231490
R. Malboosbaf, F. Azizi, Long-term treatment with antithyroid drugs: Efficacy and safety. Int. J. Endocrinol. Metab. 18(Suppl), e101487:1–10 (2020)
doi: 10.5812/ijem.101487
T. Struja, H. Fehlberg, A. Kutz, L. Guebelin, C. Degen, B. Mueller, P. Schuetz, Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis. Eur. J. Endocrinol. 176(1), 87–97 (2017)
doi: 10.1530/EJE-16-0725
pubmed: 27780830
X.G. Vos, E. Endert, A. Zwinderman, J.G. Tijssen, W.M. Wiersinga, Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 101(4), 1381–1389 (2016)
doi: 10.1210/jc.2015-3644
pubmed: 26863422
M. Preus, M. Frecker, V. Stenszky, C. BALAŠS, N. Farid, A prognostic score for Graves’ disease. Clin. Endocrinol. 23(6), 653–661 (1985)
doi: 10.1111/j.1365-2265.1985.tb01126.x
A. Allahabadia, J. Daykin, R.L. Holder, M.C. Sheppard, S.C. Gough, J.A. Franklyn, Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 85(3), 1038–1042 (2000)
pubmed: 10720036
P. Anagnostis, F. Adamidou, S.A. Polyzos, S. Katergari, E. Karathanasi, C. Zouli, A. Panagiotou, M. Kita, Predictors of long-term remission in patients with Graves’ disease: a single center experience. Endocrine 44(2), 448–453 (2013)
doi: 10.1007/s12020-013-9895-0
pubmed: 23397523
E. Masiello, G. Veronesi, D. Gallo, P. Premoli, E. Bianconi, S. Rosetti, C. Cusini, J. Sabatino, S. Ippolito, E. Piantanida, Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J. Endocrinol Investig. 41(12), 1425–1432 (2018)
doi: 10.1007/s40618-018-0918-9
T. Struja, M. Kaeslin, F. Boesiger, R. Jutzi, N. Imahorn, A. Kutz, L. Bernasconi, E. Mundwiler, B. Mueller, M. Christ-Crain et al. External validation of the GREAT score to predict relapse risk in Graves’ disease: results from a multicenter, retrospective study with 741 patients. Eur. J. Endocrinol. 176(4), 413–419 (2017)
doi: 10.1530/EJE-16-0986
pubmed: 28100628
S.S. Zuhur, G. Elbuken, I. Yildiz, P. Kadioglu, S. Erol, S. Sahin, F. Kilinc, G. Akbaba, B. Topcu, Y. Altuntas, External Validation of the GREAT Score in Turkish Patients with Graves’ Hyperthyroidism Treated with the Titration Regimen Method of Antithyroid Drugs: A Multicenter Study. Horm. Metab. Res. = Horm.- und Stoffwechselforschung = Hormones et. Metab. 51(10), 627–633 (2019)
doi: 10.1055/a-0974-3991